| STML Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the STML shares outstanding history going back to 1/29/2013:
Also see: STML Market Cap History STML YTD Return |
STML Shares Outstanding History — Stemline Therapeutics Share Count Over Time
As of 5/11/2020 Stemline Therapeutics has 52.51 million STML shares outstanding. Investors often track the STML shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows STML share count trends over time, with 33 historical shares outstanding datapoints presented, dating back to 1/29/2013.
| STML Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STML Historical Shares Outstanding: +35.00% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| STML Stock Price Chart |
| About Stemline Therapeutics Inc |
| Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. ELZONRIS® (tagraxofusp-erzs) was approved by the United States Food and Drug Administration, and is commercially available in the United States for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm. In addition, Co. is also assessing ELZONRIS, as both single agent and in combination, in a variety of other indications including Phase 1 and 2 clinical trials in chronic myelomonocytic leukemia, myelofibrosis, multiple myeloma, and acute myeloid leukemia. We show 33 historical shares outstanding datapoints in our coverage of STML's shares outstanding history. Understanding the changing numbers of STML shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like STML versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching STML by allowing them to research STML shares outstanding history as well as any other stock in our coverage universe. |
| STML Current Stock Quote |
Quotes delayed 20 minutes  Free STML Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| STML Share Performance |
| Shares Outstanding Peers |
| Stemline Therapeutics (STML) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
STOK Shares Outstanding History STRO Shares Outstanding History STSA Shares Outstanding History STSS Shares Outstanding History STTK Shares Outstanding History SUPN Shares Outstanding History SURF Shares Outstanding History SVA Shares Outstanding History SVRA Shares Outstanding History SWAV Shares Outstanding History More Healthcare companies » |
STML Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
